Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 11:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 948 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Acetaminophen Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioequivalence Study of Advil Dual Action Liquid Filled Capsules (125 mg/250 mg) Versus Advil Dual Action Caplets (125 mg/250 mg) and Bioavailability Assessment of Advil Dual Action Liquid Filled Capsules (125 mg/250 mg) and Advil Liqui-Gels (200 mg) in Healthy Adult Subjects

NCT06802185
View directory record Official record
Conditions
Pain
Interventions
ADA Liquid Filled Capsules (Test Product), ADA Caplets (Reference Product), Advil Liqui-gels (Reference Product)
Drug
Lead sponsor
HALEON
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Oct 19, 2026, 11:10 PM EDT
Completed Not applicable Interventional Results available

Intraoperative and Post-operative Analgesic Effect of IV Acetaminophen for Sinus Surgery

NCT01608308
View directory record Official record
Conditions
Chronic Sinusitis
Interventions
IV Acetaminophen, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 68 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2015 · Synced Oct 19, 2026, 11:10 PM EDT
Not listed Phase 3 Interventional

Selective Early Medical Treatment of Patent Ductus Arteriosus in Extremely Low Gestational Age Infants: A Pilot RCT

NCT05011149
View directory record Official record
Conditions
Patent Ductus Arteriosus After Premature Birth
Interventions
Ibuprofen
Drug
Lead sponsor
IWK Health Centre
Other
Eligibility
Up to 72 Hours
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
Orange, California • San Diego, California • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 21, 2024 · Synced Oct 19, 2026, 11:10 PM EDT
Completed Phase 4 Interventional

The Comparison of Supraperiosteal Nerve Block With Opiate Analgesia in Alleviating the Pain of Toothache

NCT00574015
View directory record Official record
Conditions
Toothache
Interventions
hydrocodone/acetaminophen, bupivacaine (supraperiosteal nerve block)
Drug
Lead sponsor
Albany Medical College
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Mar 24, 2014 · Synced Oct 19, 2026, 11:10 PM EDT
Withdrawn Phase 2 Interventional

Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy

NCT05574504
View directory record Official record
Conditions
Metastatic Cancer, Urothelial Carcinoma
Interventions
avelumab (PD-L1 inhibitor immunotherapy) + lurbinectedin
Drug
Lead sponsor
AdventHealth
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Oct 19, 2026, 11:10 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of a New and a Marketed Tablet Formulation Under Fasted and Fed Conditions in Healthy Adults

NCT03137017
View directory record Official record
Conditions
Opioid-Related Disorders, Pain, Acute, Pain, Postoperative
Interventions
Norco 5Mg-325Mg Tablet, GRT7014 - Abuse Deterrent Tablet
Drug
Lead sponsor
Grünenthal GmbH
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 19, 2026, 11:10 PM EDT
Withdrawn Phase 4 Interventional

Pilot Study: Effect of Dexamethasone vs Vicodin in Reducing Post-operative Pain

NCT04008043
View directory record Official record
Conditions
Oral Surgery
Interventions
Vicodin, Dexamethasone
Drug
Lead sponsor
Boston University
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Oct 19, 2026, 11:10 PM EDT
No Longer Available No phase listed Expanded access

Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma

NCT02541643
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elotuzumab
Drug
Lead sponsor
Sundar Jagannath
Other
Eligibility
18 Years and older
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 4, 2015 · Synced Oct 19, 2026, 11:10 PM EDT
Completed Early Phase 1 Interventional

Studies of Sulfur Metabolism in Humans

NCT03383133
View directory record Official record
Conditions
Metabolic Side Effects of Drugs
Interventions
SULT Allosteric Inhibition
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
61 Years to 61 Years · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 27, 2023 · Synced Oct 19, 2026, 11:10 PM EDT
Withdrawn Phase 4 Interventional

Outcome of IV Acetaminophen Use in Laparoscopic Cholecystectomies in Patients at Risk of OSA

NCT02056678
View directory record Official record
Conditions
Cholecystitis, Cholelithiasis, Obstructive Sleep Apnea
Interventions
acetaminophen, IV preparation
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2016 · Synced Oct 19, 2026, 11:10 PM EDT
Completed Phase 2Phase 3 Interventional

Low-Dose Naltrexone and Acetaminophen Combination and Sumatriptan in the Acute Treatment of Migraine With Nausea

NCT03185143
View directory record Official record
Conditions
Migraine With and Without Aura
Interventions
Naltrexone and Acetaminophen Combination, Sumatriptan 100 mg, Placebo
Drug
Lead sponsor
Allodynic Therapeutics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
North Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Oct 19, 2026, 11:10 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Utility of Pharmacogenomic Testing and Postoperative Dental Pain Outcomes

NCT02932579
View directory record Official record
Conditions
Pain
Interventions
Pharmacogenomic Testing, Ibuprofen, hydroxycontin/acetominophen, acetominophen, Oxycontin/acetominophen
Other · Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 35 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Oct 19, 2026, 11:10 PM EDT
Completed Phase 1 Interventional

Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies

NCT04681105
View directory record Official record
Conditions
Recurrent Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hairy Cell Leukemia, Recurrent Hematologic Malignancy, Recurrent Hodgkin Lymphoma, Recurrent T Acute Lymphoblastic Leukemia, Refractory Acute Leukemia, Refractory B Acute Lymphoblastic Leukemia, Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Hairy Cell Leukemia, Refractory Hematologic Malignancy, Refractory Hodgkin Lymphoma, Refractory T Acute Lymphoblastic Leukemia, Systemic Mastocytosis
Interventions
Acetaminophen, Dexamethasone, Diphenhydramine, Flotetuzumab, Ibuprofen, Ranitidine
Drug · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
12 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 19, 2026, 11:10 PM EDT
Not listed Not applicable Interventional

PDA Occlusion Using NIRS

NCT06359522
View directory record Official record
Conditions
Organ Perfusion Determined by Using NIRS Post Transcatheter PDA Occlusion or Medical Closure of PDA
Interventions
NIRS monitor
Device
Lead sponsor
University of Louisville
Other
Eligibility
0 Months to 3 Months
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 11, 2024 · Synced Oct 19, 2026, 11:10 PM EDT
Completed Phase 2 Interventional

Preeclampsia And Nonsteroidal Drugs for Analgesia: a Randomized Non Inferiority Trial

NCT03978767
View directory record Official record
Conditions
Preeclampsia Severe, Preeclampsia Postpartum
Interventions
Ibuprofen 600 mg, Ketorolac, Acetaminophen, Oxycodone
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Female only
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 19, 2026, 11:10 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

NCT04270409
View directory record Official record
Conditions
Plasma Cell Myeloma
Interventions
Isatuximab SAR650984, Lenalidomide, Dexamethasone, Montelukast or equivalent, Acetaminophen, Diphenhydramine or equivalent, Methylprednisolone or equivalent
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
337 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2033
U.S. locations
9
States / cities
Los Angeles, California • Denver, Colorado • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Oct 19, 2026, 11:10 PM EDT
Completed Phase 4 Interventional

Treatment of Cognitive and Negative Symptoms in Schizophrenia With N-acetylcysteine

NCT02505477
View directory record Official record
Conditions
Schizophrenia, Cognitive Deficits, Schizophrenia; Negative Type
Interventions
N-acetylcysteine, Treatment as Usual
Drug · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Oct 19, 2026, 11:10 PM EDT
Completed Phase 3 Interventional

Phase III Study of the Safety and Efficacy of Cl-108 in the Treatment of Moderate to Severe Pain

NCT01780428
View directory record Official record
Conditions
Pain, Nausea, Vomiting
Interventions
CL-108 (hydrodocone 7.5 mg, acetaminophen 325 mg, promethazine 12.5 mg), Placebo
Drug
Lead sponsor
Charleston Laboratories, Inc
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 3, 2016 · Synced Oct 19, 2026, 11:10 PM EDT
Completed Not applicable Interventional Results available

Randomized Controlled Trial of CES for Fibromyalgia

NCT04115033
View directory record Official record
Conditions
Fibromyalgia
Interventions
Alpha-stim
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
20 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 19, 2026, 11:10 PM EDT
Enrolling by invitation Phase 4 Interventional

A Study of Intravenous Acetaminophen for Small Bowel Obstruction

NCT05878015
View directory record Official record
Conditions
Small Bowel Obstruction
Interventions
Acetaminophen
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 19, 2026, 11:10 PM EDT
Recruiting Phase 2 Interventional

A Clinical Trial of MK-2010 With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Solid Tumors (MK-2010)

NCT07785609
View directory record Official record
Conditions
Advanced Solid Tumors, Malignant Neoplasm
Interventions
MK-2010, Sacituzumab tirumotecan, Histamine H1 Receptor Antagonist, Histamine H2 Receptor Antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent), Steroid mouthwash (dexamethasone or equivalent), Epinephrine
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 19, 2026, 11:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of MBX 1416 in Healthy Subjects

NCT06036784
View directory record Official record
Conditions
Postbariatric Hypoglycemia
Interventions
MBX 1416 (Part A), MBX 1416 (Part B), Placebo, MBX 1416 (Part C)
Drug
Lead sponsor
MBX Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Oct 19, 2026, 11:10 PM EDT
Not listed Phase 4 Interventional

ZYNRELEF® for Postoperative Analgesia After Laparoscopic Sleeve Gastrectomy

NCT05863221
View directory record Official record
Conditions
Post Operative Pain, Acute, Bariatric Surgery Candidate, Postoperative Pain
Interventions
ZYNRELEF 200Mg-6Mg Extended-Release Solution
Drug
Lead sponsor
Dr. Yannis Raftopoulos
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Holyoke, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 18, 2023 · Synced Oct 19, 2026, 11:10 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Outcomes Mandate National Integration With Cannabis as Medicine

NCT03944447
View directory record Official record
Conditions
Chronic Pain, Chronic Pain Syndrome, Chronic Pain Due to Injury, Chronic Pain Due to Trauma, Fibromyalgia, Seizures, Hepatitis C, Cancer, Crohn Disease, HIV/AIDS, Multiple Sclerosis, Traumatic Brain Injury, Sickle Cell Disease, Post Traumatic Stress Disorder, Tourette Syndrome, Ulcerative Colitis, Glaucoma, Epilepsy, Inflammatory Bowel Diseases, Parkinson Disease, Amyotrophic Lateral Sclerosis, Chronic Traumatic Encephalopathy, Anxiety, Depression, Insomnia, Autism, Opioid-use Disorder, Bipolar Disorder, Covid19, SARS-CoV Infection, COVID-19, Corona Virus Infection, Coronavirus
Interventions
Cannabis, Medical, RYAH-Medtech Inhaler
Drug · Device
Lead sponsor
OMNI Medical Services, LLC
Network
Eligibility
7 Years and older
Enrollment
200,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
17
States / cities
Boca Raton, Florida • Bradenton, Florida • Fort Lauderdale, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2022 · Synced Oct 19, 2026, 11:10 PM EDT